992 related articles for article (PubMed ID: 16117016)
21. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
Trigg ME; Higa GM
J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
[TBL] [Abstract][Full Text] [Related]
22. Anti-emetic therapy in cancer chemotherapy: current status.
Herrstedt J; Dombernowsky P
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F
Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016
[TBL] [Abstract][Full Text] [Related]
24. Clinical practice guidelines on antiemetics in oncology.
Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
[TBL] [Abstract][Full Text] [Related]
25. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
Massaro AM; Lenz KL
Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
[TBL] [Abstract][Full Text] [Related]
26. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
[TBL] [Abstract][Full Text] [Related]
27. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.
Decker GM; DeMeyer ES; Kisko DL
J Support Oncol; 2006 Jan; 4(1):35-41, 52. PubMed ID: 16444851
[TBL] [Abstract][Full Text] [Related]
28. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
29. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
30. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
[TBL] [Abstract][Full Text] [Related]
31. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and cost effectiveness of new antiemetic guidelines.
Engstrom C; Hernandez I; Haywood J; Lilenbaum R
Oncol Nurs Forum; 1999 Oct; 26(9):1453-8. PubMed ID: 11064877
[TBL] [Abstract][Full Text] [Related]
33. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy.
Tina Shih YC; Xu Y; Elting LS
Cancer; 2007 Aug; 110(3):678-85. PubMed ID: 17567835
[TBL] [Abstract][Full Text] [Related]
34. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
Oo TH; Hesketh PJ
Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
Schwartzberg LS
Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy-induced nausea and vomiting. Easing patients' fear and discomfort with effective antiemetic regimens.
Bilgrami S; Fallon BG
Postgrad Med; 1993 Oct; 94(5):55-8, 62-4. PubMed ID: 8415336
[TBL] [Abstract][Full Text] [Related]
37. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?
Sarcev T; Secen N; Zaric B; Milovancev A
J BUON; 2008; 13(3):333-9. PubMed ID: 18979546
[TBL] [Abstract][Full Text] [Related]
38. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
39. Acute and delayed nausea and emesis control in pediatric oncology patients.
Holdsworth MT; Raisch DW; Frost J
Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
[TBL] [Abstract][Full Text] [Related]
40. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]